Retatrutide, a new dual activator for both GLP-1 and glucose-dependent insulinotropic polypeptide receptors, is attracting significant attention in the nation for its likely to treat excessive weight and diabetes mellitus. This piece provides a comprehensive exploration at which drug is, how it w